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Aims: To investigate relationships between glycated haemoglobin (HbA1c) and reported hypo-
glycaemia and risk of major adverse cardiovascular events (MACE).
Methods: The EXAMINE trial randomized 5380 patients with type 2 diabetes (T2DM) and a
recent acute coronary syndrome (ACS) event, in 49 countries, to double-blind treatment
with alogliptin or placebo in addition to standard of care. We used Cox proportional
hazards models to analyse relationships among MACE, HbA1c levels and hypoglycaemic
events.
Results: Patients randomized to alogliptin achieved lower HbA1c levels than the placebo group
in all baseline HbA1c categories without differences in hypoglycaemia rates. No systematic
change was found in MACE rates according to baseline HbA1c (Pinteraction = 0.971) or HbA1c
category at 1 month. Patients in the combined treatment groups (n = 5380) who experienced
serious hypoglycaemia (n = 34) had higher MACE rates than those who did not (35.3% vs
11.4%, adjusted hazard ratio [HR] 2.42, 95% confidence interval [CI] 1.27–4.60; P = .007),
although the association was less strong when analysing only events after the hypoglycaemic
event (adjusted HR 1.60, 95% CI 0.80, 3.20).
Conclusions: There were no relationships between baseline HbA1c levels or HbA1c levels after
1 month of treatment and the risk of MACE. Alogliptin improved glycaemic control without
increasing hypoglycaemia. Reported events of hypoglycaemia and serious hypoglycaemia were
associated with MACE. These data underscore the safety of alogliptin in improving glycaemic
control in T2DM post-ACS. Further study of hypoglycaemia as an independent risk factor for
MACE in patients with T2DM and coronary disease is needed.
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1 | INTRODUCTION
In 2008, the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) study, which was designed to test the hypothesis that
intensive glucose control would reduce macrovascular disease in
patients with type 2 diabetes (T2DM) and cardiovascular risk fac-
tors, was terminated prematurely after 3.5 years because there were
22% more deaths in patients who were treated intensively.1,2 This
and other evidence prompted concern among the diabetes commu-
nity that hypoglycaemia might lead to an increase in cardiovascular
events, both fatal and non-fatal. Three lines of evidence are among
the support for the postulation that hypoglycaemia may contribute
to cardiac events: (1) experimental hypoglycaemia causes sym-
pathoadrenal activation and prolonged low-grade inflammation and
impairs endothelial function3; (2) spontaneous hypoglycaemia, partic-
ularly at night, has been associated with an increased risk of cardiac
arrhythmia4; and (3) hypoglycaemia and low levels of glycated hae-
moglobin (HbA1c) are linked to an increased risk of death in
patients with diabetes, hospitalized for myocardial infarction (MI).5
In the present analysis, we have evaluated the relationships of gly-
caemic control and reported hypoglycaemia with the risk of major
adverse cardiovascular events (MACE; cardiovascular death, non-
fatal MI, non-fatal stroke), using data from the Examination of Cardi-
ovascular Outcomes with Alogliptin versus Standard of Care
(EXAMINE) study.
The EXAMINE study showed that alogliptin, a selective dipepti-
dyl peptidase-4 (DPP-4) inhibitor approved for the treatment of
patients with T2DM, was non-inferior to placebo in its effect on
MACE in patients with T2DM and a recent acute coronary syndrome
(ACS) event.6,7 In the clinical studies conducted as part of the devel-
opment programme for alogliptin, no imbalance in cardiovascular
events, including mortality, was noted in 4168 alogliptin-treated
patients with T2DM studied relative to placebo and active compara-
tors (metformin, pioglitazone, sulphonylurea, glipizide or insulin).6 The
extent to which glycaemic control at the start of the trial and glycae-
mic control post-randomization predict cardiovascular outcomes and
anti-hyperglycaemic response to treatment is unclear. In the present
analysis, we investigated the individual effects of baseline HbA1c
level, HbA1c achieved 1 month post-randomization, final HbA1c
level, and rates of reported hypoglycaemia on MACE. We also evalu-
ated the profiles of additional anti-hyperglycaemic medication use in
each treatment arm.
2 | METHODS
The EXAMINE study was a randomized, double-blind, placebo-
controlled study of alogliptin vs placebo with standard of care for the
treatment of T2DM and secondary cardiovascular prevention in
patients who had experienced an ACS event within 15 to 90 days
prior to randomization.7 The design, patient characteristics and princi-
pal findings of the EXAMINE trial have been published previously.7,8
To be included in the trial, patients had to have a diagnosis of T2DM
requiring anti-hyperglycaemic medications with a baseline HbA1c of
6.5% to 11.0% (48-97 mmol/mol or 7.0%-10.0% [53-86 mmol/mol]
if on insulin therapy). Throughout the trial, patients were required to
receive standard of care for treatment of T2DM and cardiovascular
risk factors according to regional or national guidelines. Study-related
visits occurred at screening and randomization, as well as at 1, 3, 6, 9
and 12 months post-randomization during the first year of the
study and every 4 months during subsequent years of participation.
HbA1c values were assessed at all study visits; hypoglycaemic
events were characterized by local investigators according to their
intensity (mild to severe [requiring assistance]) and seriousness
(whether requiring hospitalization or emergency department
management).
2.1 | Statistical methods
Cox proportional hazards models were used to analyse the time to
the first occurrence of MACE for all randomized patients. The individ-
ual relationships between MACE and several measures of glycaemic
control (baseline HbA1c, HbA1c at 1 month, baseline hypoglycaemia
and incidence of hypoglycaemia) were analysed without adjustment
for multiple comparisons. The relationships among baseline HbA1c
categories and adverse events of hypoglycaemia were similarly
explored.
In the evaluations of risk of subsequent MACE according to
HbA1c category, hazard ratios (HRs) and two-sided 95% confidence
intervals (CIs) were derived from Cox proportional hazards models
with a factor for HbA1c categories, and adjusted for baseline age,
sex, duration of diabetes, smoking status, estimated glomerular filtra-
tion rate (eGFR), index ACS type and glycaemic medication (insulin,
metformin and sulphonylureas), and stratified by screening renal
function and geographic region. The group of patients with HbA1c
levels <7% served as the reference group.
In the analyses of the relationship of reported hypoglycaemia
and MACE, HRs and two-sided 95% CIs were derived from Cox pro-
portional hazards models, with a factor for hypoglycaemia incidence,
and adjusted for baseline age, sex, treatment, HbA1c, glycaemic med-
ication and stratified by screening renal function and geographic
region.
3 | RESULTS
3.1 | Baseline characteristics
The EXAMINE study enrolled 5380 patients in 49 countries who
were randomized to treatment with alogliptin (n = 2701) or placebo
(n = 2679) in addition to standard of care.7 Baseline characteristics
for these patients are presented according to reported incidence of
hypoglycaemia during the study (Table 1).
Patients who experienced hypoglycaemia during the trial had
baseline measurements indicating a longer duration of diabetes,
lower weight and a lower eGFR compared with those without
reported hypoglycaemia. A higher proportion of patients who had
hypoglycaemia were taking insulin (42.7% vs 29.0%; P < .001) or
sulphonylureas (52.0% vs 46.1%; P = .033) at baseline compared
with patients who did not have reported hypoglycaemia. In terms of
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TABLE 1 Demographic and baseline characteristics according to reported hypoglycaemia during the study
Any reported hypoglycaemia (N = 354) No reported hypoglycaemia (N = 5026) P
Treatment assignment, % (n/N) .719
Alogliptin 51.1 (181/354) 50.1 (2520/5026)
Placebo 48.9 (173/354) 49.9 (2506/5026)
Age
Mean  s.d. (N) 62  9 (354) 61  10 (5026) .057
Age ≥ 65 years, % (n/N) 39.0 (138/354) 35.2 (1769/5026) .150
Male, % (n/N) 63.6 (225/354) 68.2 (3426/5026) .073
Duration of diabetes, years
Mean  s.d. (N) 12.0  8.7 (353) 9.0  8.1 (5006) <.001
Baseline HbA1c concentration
Mean  s.d. (N) 8.0  1.0 (354) 8.0  1.1 (5025) .701
Body weight, kg
Mean  s.d. (N) 77.5  20.0 (354) 82.5  19.1 (5026) <.001
BMI, kg/m2
Mean  s.d. (N) 28.7  6.2 (354) 29.5  5.5 (5025) .016
Race, % (n/N) .040
American-Indian or Alaska Native 2.0 (7/354) 2.0 (103/5026)
Asian 26.6 (94/354) 19.8 (995/5026)
Black or African-American 5.1 (18/354) 3.9 (198/5026)
Native Hawaiian or Other Pacific Islander 0.3 (1/354) 0.2 (10/5026)
White 65.5 (232/354) 73.2 (3677/5026)
Multiracial 0.6 (2/354) 0.9 (43/5026)
Region of world, % (n/N) <.001
USA, Canada 16.1 (57/354) 15.8 (796/5026)
Western Europe, Australia, New Zealand and
Middle East
10.5 (37/354) 11.5 (579/5026)
Central and South America, Mexico 40.7 (144/354) 24.9 (1249/5026)
Eastern Europe and Africa 6.8 (24/354) 29.5 (1484/5026)
Asia, Pacific Islands 26.0 (92/354) 18.3 (918/5026)
Cardiovascular risk factors and history, % (n/N)
Current smoker 9.0 (32/354) 14.0 (702/5026) .033
Hypertension 82.8 (293/354) 83.1 (4176/5026) .877
Myocardial infarction 87.6 (310/354) 88.0 (4424/5026) .801
PCI 61.6 (218/354) 62.8 (3154/5026) .660
CABG 16.1 (57/354) 12.6 (631/5026) .053
Congestive heart failure 26.3 (93/354) 28.0 (1408/5026) .480
Cerebrovascular accident 7.1 (25/354) 7.2 (363/5026) .910
Peripheral arterial disease 13.6 (48/354) 9.3 (466/5026) .008
Renal function eGFR, mL/min/1.73 m2
Mean  s.d. (N) 62.6  20.9 (354) 71.5  21.3 (5026) <.001
eGFR < 60 mL/min/1.73 m2, % (n/N) 43.2 (153/354) 28.1 (1412/5026) <.001
Index ACS event .351
Myocardial infarction 79.4 (281/354) 77.2 (3871/5012)
Unstable angina 20.6 (73/354) 22.8 (1141/5012)
Time from index ACS event to randomization, days
Mean  s.d. (N) 48.1  21.5 (354) 47.8  22.0 (5012) .787
Glycaemic medication, % (n/N)
Insulin 42.7 (151/354) 29.0 (1456/5026) <.001
Metformin 63.0 (223/354) 66.6 (3349/5026) .161
Sulphonylureas 52.0 (184/354) 46.1 (2319/5026) .033
Abbreviations: BMI, body mass index; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; s.d., standard deviation.
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regional differences, patients from Asia and the Pacific Islands, as
well as those from Central and South America, experienced an
increased incidence of reported hypoglycaemia; by contrast, patients
from Eastern Europe and Africa experienced a very low incidence of
reported hypoglycaemia.
At baseline, 29.4% (793/2701) and 30.4% (814/2679) of patients
in the alogliptin and placebo groups, respectively, were receiving
insulin, and at month 16, these proportions had risen to 31.6%
(595/1880) and 35.8% (658/1838) of patients (P = .007, Pearson’s
chi-squared test). Similar increases were observed in the proportions
of patients taking metformin, sulphonylureas, and thiazolidinediones
(Supporting Information, Table S1).
3.2 | Changes in HbA1c
From baseline to the end of the study, there was a consistently
significant relative reduction in HbA1c in the alogliptin group as
compared with placebo in each baseline HbA1c category
(Figure 1). The least-squares mean difference in change from
baseline between alogliptin and placebo was most pronounced for
patients with HbA1c ≥ 9.0% (75 mmol/mol) at baseline (least-
squares mean difference −0.54% [6 mmol/mol], 95% CI −0.74%,
−0.34%; P < .001).
Regardless of treatment group, most patients (3118 [58%]) had
an HbA1c of <7% measured on at least 1 study visit, with
918 patients (17%) in that HbA1c category at baseline and 1599
patients (30%) by 1 month; 1519 (28%) others would achieve HbA1c
<7% at some point after 1 month. By contrast, 785 patients (14.6%)
did not have an HbA1c <8% during the study and 246 (4.6%) patients
did not have an HbA1c <9%. Among patients whose lowest HbA1c
level was ≥8%, the proportion of patients treated with placebo was
larger (478 [8.9%]) than for those treated with alogliptin (307 [5.7%];
Supporting Information, Table S2).
3.3 | HbA1c and cardiovascular outcomes
For each baseline HbA1c category, the rates of MACE composite
events and individual event types occurring by the end of the study
were similar between treatment groups (Figure 2). Relative to the cat-
egory of patients with HbA1c <7% at baseline, patients in higher
categories did not have any altered risk for the composite of MACE
or any of the component events, and the same was true for HbA1c
category at 1 month (Figure 3). There was also no change in risk of
hospitalization for heart failure or the composite risk of cardiovascu-
lar death and hospitalization for heart failure according to baseline
HbA1c category.
3.4 | Cardiovascular outcome associated with the
incidence of reported hypoglycaemia
Adjusting for baseline covariates and study treatment, there was a
significant association of MACE with patients who had an episode of
serious hypoglycaemia (12/34 [35.3%]) vs those who did not
(609/5346 [11.4%]; adjusted HR 2.42, 95% CI 1.27-4.60; P = .007
[Figure 4A]). An association with MACE was also found for patients
with any hypoglycaemia (64/354 [18.1%]) vs those without
(557/5026 [11.1%]; adjusted HR 1.38, 95% CI 1.05-1.80; P = .019).
When limiting the analysis only to MACE that occurred subsequent
to a reported hypoglycaemic event, the association was less robust
and not statistically significant (Figure 4B). There was no appreciable
difference between treatment groups in MACE rates for patients with
or without hypoglycaemia.
3.5 | Hypoglycaemia based on HbA1c at baseline
and end of study
Overall, 354 patients (6.6%) were reported to have hypoglycaemia
(6.7% with alogliptin and 6.5% with placebo); rates of serious
FIGURE 1 Change in HbA1c from baseline to last visit by baseline HbA1c category and treatment group analysed using Cox proportional
hazards models without adjustment for multiple comparisons. LS, least squares.
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hypoglycaemia were low (0.7% with alogliptin and 0.6% with pla-
cebo). There were no significant differences in the rates of all
reported hypoglycaemia or serious hypoglycaemia between the
alogliptin and placebo groups for any category of baseline HbA1c
value. Serious hypoglycaemic events occurred only in patients in both
randomized treatment arms who were taking insulin and/or
FIGURE 2 Percentage of patients experiencing MACE and composite by baseline HbA1c category and treatment group: HRs and P values for
the primary endpoint of composite MACE with alogliptin vs placebo. Relationships between MACE and baseline HbA1c were analysed using
Cox proportional hazards models without adjustment for multiple comparisons.
FIGURE 3 Risk of MACE outcomes based
on HbA1c at 1 month. Combined event
rate (both treatment groups). For analysis
of MACE by categories of HbA1c, only the
first event after 1-month HbA1c
measurement is included in the analysis for
each patient. HRs and 95% CIs are derived
from Cox proportional hazards models with
a factor for HbA1c categories at 1 month
and adjusted by age, sex, duration of
diabetes, smoking status, renal function
eGFR, index ACS type, glycaemic
medication (insulin, metformin and
sulphonylureas) at baseline and stratified
by screening renal function and geographic
region. The group of patients with
HbA1c < 7% at 1 month is the reference
group.
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sulphonylureas and who had a comorbid event, such as inability to
eat or intercurrent gastrointestinal illnesses.
4 | DISCUSSION
In the present analysis of the relationship of glycaemic control and
reported hypoglycaemia to MACE in patients with T2DM and a
recent ACS, we found no relationship between HbA1c levels and
MACE as previously observed in individuals with or without unstable
cardiovascular disease; however, we did find an interesting associa-
tion between hypoglycaemia and cardiac events in this patient
population.
Patients in the EXAMINE trial had baseline T2DM and a recent
history of an ACS, making them a high cardiovascular risk population.
The highest event rates of MACE (12.8% at 2 years) were reported
for patients with a baseline HbA1c of between 8% and 9%, although
these did not differ notably from rates seen in the other categories.
Patients in the alogliptin arm achieved a lower HbA1c than those on
placebo regardless of their baseline HbA1c category. After initiation
of treatment with alogliptin or placebo, there was a greater use of
add-on medications in the placebo group, although this was insuffi-
cient to match HbA1c levels in the group treated with alogliptin.
Using the combined group of patients with HbA1c <7% at 1 month
(allowing for treatment effect) as a reference, we found no increase
in risk of subsequent MACE for categories of higher HbA1c levels,
and the same was true when the analysis was performed for cate-
gories of HbA1c at baseline. This contrasts with a previous analysis
of data from a trial of saxagliptin vs placebo in lower risk patients
with T2DM and stable cardiovascular disease or atherosclerotic risk
factors (SAVOR-TIMI 53), which showed that categories of higher
baseline HbA1c (>7%) were associated with a higher risk of MACE.9
This may reflect different populations; those in the EXAMINE trial,
who were on average 45 days from a previous ACS at baseline, expe-
rienced MACE at a rate approximately double that of patients in the
SAVOR-TIMI 53 trial, and their enhanced cardiovascular risk may
have masked a modest effect of glycaemic control.
In the entire EXAMINE cohort, reported events of any hypogly-
caemia and serious hypoglycaemia were associated with the primary
endpoint of MACE. A stronger relationship between serious hypogly-
caemic events (compared to any hypoglycaemic event) and MACE
could indicate a dose–response effect, although reporting of serious
FIGURE 4 Risk of MACE outcomes based on reported hypoglycaemia for (A) any MACE and (B) subsequent MACE. Hypoglycaemia incidence is
based on reported adverse events of the hypoglycaemia preferred term coded according to the Medical Dictionary for Regulatory Activities.
HRs and 2-sided 95% CIs are derived from Cox proportional hazards models with a factor for hypoglycaemia incidence and adjusted by baseline
age, sex, treatment, HbA1c and glycaemic medication (insulin, metformin and sulphonylureas) and stratified by screening renal function and
geographic region.
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hypoglycaemia was also probably more reliable. A review of patients
with serious hypoglycaemia found that all were taking concomitant
insulin or sulphonylureas and usually had a comorbid gastrointestinal
event or were anorectic and failed to eat on the day of the hypogly-
caemic event. In light of the limitations of the frequency of data collec-
tion and the inclusion only of reported events with the preferred term
of “hypoglycaemia,” it is likely that non-serious episodes of hypogly-
caemia were more frequent than reported in the study population.
Additionally, the different definition of serious as opposed to severe
hypoglycaemia may have contributed to the lower rates of hypogly-
caemia overall than have been reported in other comparable trials.
The more robust relationship between hypoglycaemia and any
MACE, as opposed to MACE after hypoglycaemia, suggests that con-
founding contributes to these findings; namely, that hypoglycaemia is
associated with a comorbidity that increases the likelihood of MACE.
The potential contribution of hypoglycaemia to subsequent cardiovascu-
lar mortality in individuals with T2DM has been the subject of considera-
ble debate since the premature closure of the ACCORD trial because of
an increased mortality rate in the intensive glycaemic control group.1
Rates of severe hypoglycaemia were considerably higher in the inten-
sively treated group (16.2% vs 5.1% in the standard treatment group)
but were one of a number of potential causes of increased mortality
which included weight gain, specific medications or chance. Further-
more, subsequent sub-analyses were cited by the ACCORD investiga-
tors as excluding severe hypoglycaemia as a cause of mortality.10
Nevertheless, 2 other trials measuring the impact of intensive glu-
cose control on macrovascular disease in individuals with T2DM, with
very different rates of severe hypoglycaemia, the ADVANCE study
(2.7% vs 1.5%, intensive vs standard) and the VADT study (21.2%
vs. 9.9%, intensive vs standard), which were contemporary with
ACCORD, have reported strong associations between a severe hypo-
glycaemic event and subsequent mortality.11,12 The ADVANCE inves-
tigators highlighted the potential contribution of confounding to their
reported association13; however, a recent meta-analysis which
included data on six large observational studies involving >900 000
patients used a statistical approach – bias analysis – to show that con-
founding as a result of comorbid severe illness was unlikely to explain
the whole association.5 The authors concluded that there was, in fact,
a strong likelihood of a direct relationship between hypoglycaemic epi-
sodes and subsequent cardiovascular events. ACCORD did not evalu-
ate a direct effect of hypoglycaemia on risk of cardiovascular death or
determine a definite reason for increased cardiovascular death among
patients treated intensively. By contrast, the ADVANCE study found
higher risk in patients who had an episode of severe hypoglycaemia
for vascular events, cardiovascular death and death from any cause –
and speculated such hypoglycaemia episodes could be only markers
for susceptibility; any causative contribution of hypoglycaemia to risk
of cardiovascular events remains uncertain.1,13 More recent results
from the SAVOR-TIMI 53 study in patients with T2DM and renal
impairment have shown an increase in hypoglycaemia and major cardi-
ovascular events in patients with moderate but not severe renal
impairment, potentially attributable to higher rates of concomitant
medication use in the moderately impaired group.14
In conclusion, alogliptin improved glycaemic control without
increasing hypoglycaemia. We found no association between baseline
HbA1c levels or HbA1c levels within 1 month of initiating treatment
with the risk of MACE. Reported “serious” hypoglycaemic events
were significantly associated with MACE but when the analysis was
limited to MACE that occurred subsequent to a serious hypoglycae-
mic event, the association was less robust and no longer statistically
significant. These data underscore the safety of alogliptin in improv-
ing glycaemic control in T2DM post-ACS. Together with findings
from the ADVANCE, ACCORD and SAVOR-TIMI 53 trials, the find-
ings of the present analysis support the notion that events of incapa-
citating hypoglycaemia in T2DM may portend increased risk of major
cardiovascular events, in which the concomitant use of insulin and/or
sulphonylureas with a DPP-4 inhibitor may play a role. Further
research is warranted to understand the temporal relationship and
prognostic value of hypoglycaemia in patients treated for T2DM to
events of the MACE composite.
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